胆固醇代谢途径中相关因子与非酒精性脂肪性肝病的研究
Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease
摘要: 非酒精性脂肪性肝病(非酒精性脂肪性肝炎为其严重的亚型)已为我国最常见的慢性肝脏疾病，其发病率仍逐年增加。目前，关于非酒精性脂肪性肝病的发病机制，被广泛认可的是“多重打击学说”，在该学说中的“胆固醇代谢”也被众多学者所关注。因此，本文结合近几年胆固醇代谢途径中相关因子对非酒精性脂肪性肝病的发病机制进行阐述，以期为该病的临床治疗及研究提供相关参考。
Abstract: Non-alcoholic fatty liver disease (non-alcoholic steatohepatitis is its serious subtype) has been the most common chronic liver disease in China, and its incidence is still increasing year by year. At present, the pathogenesis of nonalcoholic fatty liver disease is widely recognized as the “multi-hit theory”, and the “cholesterol metabolism” in this theory has also been concerned by many scholars. Therefore, in this paper, the pathogenesis of nonalcoholic fatty liver disease is described in combination with the relevant factors in the cholesterol metabolic pathway in recent years in order to provide a relevant reference for the clinical treatment and research of the disease.
文章引用：张越, 刘冀. 胆固醇代谢途径中相关因子与非酒精性脂肪性肝病的研究[J]. 临床医学进展, 2022, 12(4): 3703-3709. https://doi.org/10.12677/ACM.2022.124534

参考文献

[1] Kerr, T.A. and Davidson, N.O. (2012) Cholesterol and Nonalcoholic Fatty Liver Disease: Renewed Focus on an Old Villain. Hepatology, 56, 1995-1998. [Google Scholar] [CrossRef] [PubMed]
[2] Eguchi, Y., Hyogo, H., Ono, M., et al. (2012) Prevalence and Associated Metabolic Factors of Nonalcoholic Fatty Liver Disease in the General Population from 2009 to 2010 in Japan: A Multicenter Large Retrospective Study. Journal of Gastroenterology, 47, 586-595. [Google Scholar] [CrossRef] [PubMed]
[3] Estes, C., Anstee, Q.M., Arias-Loste, M.T., et al. (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016-2030. Journal of Hepatology, 69, 896-904. [Google Scholar] [CrossRef] [PubMed]
[4] Qiu, Y., Sui, X., Zhan, Y., et al. (2017) Steroidogenic Acute Regulatory Protein (StAR) Overexpression Attenuates HFD-Induced Hepatic Steatosis and Insulin Resistance. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1863, 978-990. [Google Scholar] [CrossRef] [PubMed]
[5] 路晓荣, 李剑勇. 动物机体胆固醇代谢调控机制研究进展[J]. 动物医学进展, 2019, 40(7): 101-107.
[6] Maxfield, F.R. and Tabas, I. (2005) Role of Cholesterol and Lipid Organization in Disease. Nature, 438, 612-621. [Google Scholar] [CrossRef] [PubMed]
[7] Kapourchali, F.R., Surendiran, G., Goulet, A. and Moghadasian, M.H. (2016) The Role of Dietary Cholesterol in Lipoprotein Metabolism and Related Metabolic Abnormalities: A Mini-Review. Critical Reviews in Food Science and Nutrition, 56, 2408-2415. [Google Scholar] [CrossRef] [PubMed]
[8] Trapani, L., Segatto, M. and Pallottini, V. (2012) Regulation and Deregulation of Cholesterol Homeostasis: The Liver as a Metabolic “Power Station”. World Journal of Hepatology, 4, 184-190. [Google Scholar] [CrossRef] [PubMed]
[9] Zhou, F. and Sun, X. (2021) Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 9, Article ID: 762828. [Google Scholar] [CrossRef] [PubMed]
[10] Malhotra, P., Gill, R.K., Saksena, S. and Alrefai, W.A. (2020) Disturbances in Cholesterol Homeostasis and Non-Alcoholic Fatty Liver Diseases. Frontiers in Medicine, 7, Article No. 467. [Google Scholar] [CrossRef] [PubMed]
[11] Alkhouri, N., Dixon, L.J. and Feldstein, A.E. (2009) Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids Are Created Equal. Expert Review of Gastroenterology & Hepatology, 3, 445-451. [Google Scholar] [CrossRef] [PubMed]
[12] Takakura, K., Oikawa, T., Nakano, M., et al. (2019) Recent Insights into the Multiple Pathways Driving Non-alcoholic Steatohepatitis-Derived Hepatocellular Carcinoma. Frontiers in Oncology, 9, Article No. 762. [Google Scholar] [CrossRef] [PubMed]
[13] Min, H.K., Kapoor, A., Fuchs, M., et al. (2012) Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease. Cell Metabolism, 15, 665-674. [Google Scholar] [CrossRef] [PubMed]
[14] Liu, M.X., Gao, M., Li, C.Z., et al. (2017) Dicer1/miR-29/HMGCR Axis Contributes to Hepatic Free Cholesterol Accumulation in Mouse Non-Alcoholic Steatohepatitis. Acta Pharmacologica Sinica, 38, 660-671. [Google Scholar] [CrossRef] [PubMed]
[15] Johnson, B.M. and DeBose-Boyd, R.A. (2018) Underlying Mechanisms for Sterol-Induced Ubiquitination and ER-Associated Degradation of HMG CoA Reductase. Seminars in Cell & Developmental Biology, 81, 121-128. [Google Scholar] [CrossRef] [PubMed]
[16] Sun, C., Huang, F., Liu, X., et al. (2015) MiR-21 Regulates Triglyceride and Cholesterol Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting HMGCR. International Journal of Molecular Medicine, 35, 847-853. [Google Scholar] [CrossRef] [PubMed]
[17] Takei, A., Nagashima, S., Takei, S., et al. (2020) Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice. Diabetes, 69, 158-164. [Google Scholar] [CrossRef] [PubMed]
[18] Enjoji, M., Yasutake, K., Kohjima, M. and Nakamuta, M. (2012) Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol. International Journal of Hepatology, 2012, Article ID: 925807. [Google Scholar] [CrossRef] [PubMed]
[19] Marí, M., Caballero, F., Colell, A., et al. (2006) Mitochondrial Free Cholesterol Loading Sensitizes to TNF- and Fas-Mediated Steatohepatitis. Cell Metabolism, 4, 185-198. [Google Scholar] [CrossRef] [PubMed]
[20] Brown, M.S., Radhakrishnan, A. and Goldstein, J.L. (2018) Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annual Review of Biochemistry, 87, 783-807. [Google Scholar] [CrossRef] [PubMed]
[21] Van Rooyen, D.M. and Farrell, G.C. (2011) SREBP-2: A Link between Insulin Resistance, Hepatic Cholesterol, and Inflammation in NASH. Journal of Gastroenterology and Hepatology, 26, 789-792. [Google Scholar] [CrossRef] [PubMed]
[22] Nakamuta, M., Fujino, T., Yada, R., et al. (2009) Impact of Cholesterol Metabolism and the LXRalpha-SREBP-1c Pathway on Nonalcoholic Fatty Liver Disease. International Journal of Molecular Medicine, 23, 603-608. [Google Scholar] [CrossRef] [PubMed]
[23] Zhao, L., Chen, Y., Tang, R., et al. (2011) Inflammatory Stress Exacerbates Hepatic Cholesterol Accumulation via Increasing Cholesterol Uptake and de Novo Synthesis. Journal of Gastroenterology and Hepatology, 26, 875-883. [Google Scholar] [CrossRef] [PubMed]
[24] Cheung, O., Puri, P., Eicken, C., et al. (2008) Nonalcoholic Steatohepatitis Is Associated with Altered Hepatic MicroRNA Expression. Hepatology, 48, 1810-1820. [Google Scholar] [CrossRef] [PubMed]
[25] Xie, X., Liao, H., Dang, H., et al. (2009) Down-Regulation of Hepatic HNF4alpha Gene Expression during Hyperinsulinemia via SREBPs. Molecular Endocrinology, 23, 434-443. [Google Scholar] [CrossRef] [PubMed]
[26] Malhotra, P., Aloman, C., Ankireddy, A., et al. (2017) Overactivation of Intestinal Sterol Response Element-Binding Protein 2 Promotes Diet-Induced Nonalcoholic Steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 313, G376-G385. [Google Scholar] [CrossRef] [PubMed]
[27] Svegliati-Baroni, G., Pierantonelli, I., Torquato, P., et al. (2019) Lipidomic Biomarkers and Mechanisms of lipotoXicity in Non-Alcoholic Fatty Liver Disease. Free Radical Biology and Medicine, 144, 293-309. [Google Scholar] [CrossRef] [PubMed]
[28] Li, H., Yu, X.H., Ou, X., et al. (2021) Hepatic Cholesterol Transport and Its Role in Non-Alcoholic Fatty Liver Disease and Atherosclerosis. Progress in Lipid Research, 83, Article ID: 101109. [Google Scholar] [CrossRef] [PubMed]
[29] Lyu, J., Imachi, H., Fukunaga, K., et al. (2020) Role of ATP-Binding Cassette Transporter A1 in Suppressing Lipid Accumulation by Glucagon-Like Peptide-1 Agonist in Hepatocytes. Molecular Metabolism, 34, 16-26. [Google Scholar] [CrossRef] [PubMed]
[30] Vega-Badillo, J., Gutiérrez-Vidal, R., Hernández-Pérez, H.A., et al. (2016) Hepatic miR-33a/miR-144 and Their Target Gene ABCA1 Are Associated with Steatohepatitis in Morbidly Obese Subjects. Liver International, 36, 1383-1391. [Google Scholar] [CrossRef] [PubMed]
[31] Yoon, H.Y., Lee, M.H., Song, Y., et al. (2021) ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis. Frontiers in Endocrinology, 12, Article ID: 639524. [Google Scholar] [CrossRef] [PubMed]
[32] Costet, P., Luo, Y., Wang, N., et al. (2000) Sterol-Dependent Transactivation of the ABC1 Promoter by the Liver X Receptor/Retinoid X Receptor. Journal of Biological Chemistry, 275, 28240-28245. [Google Scholar] [CrossRef] 
[33] Ioannou, G.N., Morrow, O.B., Connole, M.L. and Lee, S.P. (2009) Association between Dietary Nutrient Composition and the Incidence of Cirrhosis or Liver Cancer in the United States Population. Hepatology, 50, 175-184. [Google Scholar] [CrossRef] [PubMed]
[34] Van Rooyen, D.M., Larter, C.Z., Haigh, W.G., et al. (2011) Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis. Gastroenterology, 141, 1393-1403.E5. [Google Scholar] [CrossRef] [PubMed]
[35] Yasutake, K., Nakamuta, M., Shima, Y., et al. (2009) Nutritional Investigation of Non-Obese Patients with Non-Alcoholic Fatty Liver Disease: The Significance of Dietary Cholesterol. Scandinavian Journal of Gastroenterology, 44, 471-477. [Google Scholar] [CrossRef] [PubMed]
[36] Musso, G., Gambino, R., De Michieli, F., et al. (2003) Dietary Habits and Their Relations to Insulin Resistance and Postprandial Lipemia in Nonalcoholic Steatohepatitis. Hepatology, 37, 909-916. [Google Scholar] [CrossRef] [PubMed]
[37] Henkel, J., Alfine, E., Sain, J., et al. (2018) Soybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary Cholesterol. Nutrients, 10, Article No. 1326. [Google Scholar] [CrossRef] [PubMed]
[38] Comhair, T.M., et al. (2011) Dietary Cholesterol, Female Gender and n-3 Fatty Acid Deficiency Are More Important Factors in the Development of Non-Alcoholic Fatty Liver Disease than the Saturation Index of the Fat. Nutrition & Metabolism, 8, 4.
[39] Marchesini, G., Petta, S. and Dalle, G.R. (2016) Diet, Weight Loss, and Liver Health in Nonalcoholic Fatty Liver Disease: Pathophysiology, Evidence, and Practice. Hepatology, 63, 2032-2043. [Google Scholar] [CrossRef] [PubMed]
[40] Dongiovanni, P., Petta, S., Mannisto, V., et al. (2015) Statin Use and Non-Alcoholic Steatohepatitis in at Risk Individuals. Journal of Hepatology, 63, 705-712. [Google Scholar] [CrossRef] [PubMed]
[41] Muraoka, T., Aoki, K., Iwasaki, T., et al. (2011) Ezetimibe Decreases SREBP-1c Expression in Liver and Reverses Hepatic Insulin Resistance in Mice Fed a High-Fat Diet. Metabolism, 60, 617-628. [Google Scholar] [CrossRef] [PubMed]
[42] Jun, B.G. and Cheon, G.J. (2019) The Utility of Ezetimibe Therapy in Nonalcoholic Fatty Liver Disease. The Korean Journal of Internal Medicine, 34, 284-285. [Google Scholar] [CrossRef] [PubMed]
[43] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. (2015) Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial. The Lancet, 385, 956-965. [Google Scholar] [CrossRef] 

为你推荐